CN101415407B - Jun n-末端激酶抑制剂治疗青光眼的用途 - Google Patents

Jun n-末端激酶抑制剂治疗青光眼的用途 Download PDF

Info

Publication number
CN101415407B
CN101415407B CN2007800116928A CN200780011692A CN101415407B CN 101415407 B CN101415407 B CN 101415407B CN 2007800116928 A CN2007800116928 A CN 2007800116928A CN 200780011692 A CN200780011692 A CN 200780011692A CN 101415407 B CN101415407 B CN 101415407B
Authority
CN
China
Prior art keywords
cell
jnk
people
jnk inhibitor
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800116928A
Other languages
English (en)
Chinese (zh)
Other versions
CN101415407A (zh
Inventor
D·L·弗利纳
彭玉豪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN101415407A publication Critical patent/CN101415407A/zh
Application granted granted Critical
Publication of CN101415407B publication Critical patent/CN101415407B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2007800116928A 2006-03-31 2007-03-14 Jun n-末端激酶抑制剂治疗青光眼的用途 Expired - Fee Related CN101415407B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/394,893 US7803824B2 (en) 2004-10-29 2006-03-31 Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US11/394,893 2006-03-31
PCT/US2007/063961 WO2007117849A2 (en) 2006-03-31 2007-03-14 Use of inhibitors of jun n-terminal kinases to treat glaucoma

Publications (2)

Publication Number Publication Date
CN101415407A CN101415407A (zh) 2009-04-22
CN101415407B true CN101415407B (zh) 2011-05-11

Family

ID=38523463

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800116928A Expired - Fee Related CN101415407B (zh) 2006-03-31 2007-03-14 Jun n-末端激酶抑制剂治疗青光眼的用途

Country Status (13)

Country Link
US (3) US7803824B2 (enExample)
EP (1) EP2004158A2 (enExample)
JP (1) JP5241033B2 (enExample)
KR (1) KR20080108503A (enExample)
CN (1) CN101415407B (enExample)
AR (1) AR060222A1 (enExample)
AU (1) AU2007235111B2 (enExample)
BR (1) BRPI0710099A2 (enExample)
CA (1) CA2644721A1 (enExample)
MX (1) MX2008011319A (enExample)
TW (1) TWI419694B (enExample)
WO (1) WO2007117849A2 (enExample)
ZA (1) ZA200807667B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
WO2010151638A1 (en) * 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
AU2014301631A1 (en) * 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
AU2015281361A1 (en) * 2014-06-26 2016-11-17 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121932A1 (en) * 1998-10-13 2001-08-08 Kyowa Hakko Kogyo Co., Ltd. Remedies for ocular diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040847A1 (en) * 1996-04-26 1997-11-06 University Of Ottawa Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
ATE253062T1 (de) 1998-12-17 2003-11-15 Hoffmann La Roche 4- und 5-alkynyloxindole sowie 4- und 5- alkenyloxindole
EP1175399B1 (en) 1999-04-23 2009-03-11 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
CZ2002534A3 (cs) 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitory protein-kináz, farmaceutické prostředky, které je obsahují, a jejich pouľití
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
CN1304375C (zh) 1999-08-19 2007-03-14 信号药品公司 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1289523A1 (en) 2000-06-01 2003-03-12 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
EP1193256A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
CA2437248A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
WO2003018020A1 (en) 2001-08-23 2003-03-06 Takeda Chemical Industries, Ltd. Jnk inhibitors
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
JP2003129190A (ja) 2001-10-19 2003-05-08 Sumitomo Metal Ind Ltd マルテンサイト系ステンレス鋼およびその製造方法
US20030138819A1 (en) 2001-10-26 2003-07-24 Haiqing Gong Method for detecting disease
ATE465153T1 (de) * 2002-02-28 2010-05-15 Eisai R&D Man Co Ltd Neue indazolverbindungen mit kondensiertem ring
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제
US7465736B2 (en) 2002-06-14 2008-12-16 Laboratoires Serono S.A. Azole methylidene cyanide derivatives and their use as protein kinase modulators
CA2497977A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20040092568A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121932A1 (en) * 1998-10-13 2001-08-08 Kyowa Hakko Kogyo Co., Ltd. Remedies for ocular diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Philippe P. Roux,et al.K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage Kinase-3 and induce activation of Akt and ERK.The Journal of Biological Chemistry.2002,277(51),49473-49480. *
Sonia Carboni,et al.AS601245(1,3-benzothiazol-2-yl(2-{[2-(3-pyridinyl)ethyl] amino} -4 pyrimidinyl) acetonitrile):a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties.The Journal of Pharmacology and Experimental Therapeutics.2004,310(1),25-32.
Sonia Carboni,et al.AS601245(1,3-benzothiazol-2-yl(2-{[2-(3-pyridinyl)ethyl] amino}-4 pyrimidinyl) acetonitrile):a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties.The Journal of Pharmacology and Experimental Therapeutics.2004,310(1),25-32. *

Also Published As

Publication number Publication date
BRPI0710099A2 (pt) 2011-08-02
US20120004274A1 (en) 2012-01-05
US20100311716A1 (en) 2010-12-09
TWI419694B (zh) 2013-12-21
ZA200807667B (en) 2010-07-28
EP2004158A2 (en) 2008-12-24
WO2007117849A2 (en) 2007-10-18
TW200744601A (en) 2007-12-16
KR20080108503A (ko) 2008-12-15
AR060222A1 (es) 2008-06-04
AU2007235111A1 (en) 2007-10-18
JP2009532373A (ja) 2009-09-10
AU2007235111B2 (en) 2012-03-22
US20060172991A1 (en) 2006-08-03
CN101415407A (zh) 2009-04-22
JP5241033B2 (ja) 2013-07-17
CA2644721A1 (en) 2007-10-18
US7803824B2 (en) 2010-09-28
MX2008011319A (es) 2008-09-19
WO2007117849A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
CN101415407B (zh) Jun n-末端激酶抑制剂治疗青光眼的用途
US20100280089A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
JP6868014B2 (ja) 翼状片を治療するための組成物及び方法
Tokushige et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys
Patel et al. Dexamethasone-induced ocular hypertension in mice: effects of myocilin and route of administration
EP2319539A1 (en) Prophylactic or therapeutic agent for axial myopia
EP1752456B1 (en) Corneal perception recovery drug containing amide compound
JP2023035974A (ja) ナノ低分子ペプチドｆｇ及びその眼底血管疾患の治療や予防用薬物の調製への応用
KR20040014600A (ko) 알파1 수용체 차단약을 유효 성분으로 하는 시신경 보호제
KR20140041459A (ko) 초기 녹내장에서 정상적인 시각 기능을 회복시키는 ｐａｃａｐ에 기반한 안과용 제제
Maddineni et al. Mouse Model of Glucocorticoid-Induced Glaucoma
US20210061800A1 (en) Compounds for treating eye diseases and methods thereof
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
AU2011205120A1 (en) Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
Yuan et al. Leonurine alleviates retinal ischemia-reperfusion injury by inhibiting microglia activation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110511

Termination date: 20150314

EXPY Termination of patent right or utility model